To use leading-edge techniques & strategies to harness the immune system as a powerful new approach to cancer therapy.
With recent technology advances, it has become possible to dissect the immune response to patient-specific neoantigens, which is critical in mediating a tumor-specific immune response against cancer. Understanding neoantigen-specific T cells and their innate immune regulation is critical for the development of novel personalized cancer immunotherapy.
Michael W. Washabaugh, Ph.D.
Chief Executive Officer
Teresa G. Hayes, M.D., Ph.D.
Chief Medical Officer
Donald Payne, MBA, CPA
Chief Financial Officer
A therapeutic HLA-restricted peptide vaccine for the treatment of NY-ESO-1-positive solid cancers. A Phase I trial demonstrated feasibility & potential biologic anti-tumor activity for the peptide component of the vaccine (NCT00616291).
A combination therapy of IMT-001 plus an anti-PD-1 blockade.
A combination therapy of IMT-001 plus a Treg cell checkpoint blockade.
The information on this website, including any investor downloads, is not an offer to sell or solicitation of an offer to buy any interest in the company. Any offer of solicitation will be made only by means of a confidential private offering memorandum relating to any such interest in the company and solely in those jurisdictions where permitted by law.
We ask that you review our “Legal Notice” section of the website, which includes important information you should consider. The Legal Notice includes information relating to, among other things, use of and reliance upon the content of this website, our use of forward looking information and other important disclaimers. Please contact us if you have any questions.
All statements other than historical facts are forward–looking statements and are based on the current expectations, forecasts, and assumptions of Immunova Therapeutics, Inc.
This site may be considered advertising under certain jurisdictions. Prior results do not guarantee a similar outcome.
Immunova Therapeutics, Inc. and the Immunova Therapeutics logo are trademarks of Immunova Therapeutics, Inc. Other marks herein are the properties of their respective owners.
Available upon request.
Announce events so everybody knows and gets excited about it.
Let folks know when we open a new location, secure funding, or reach a clinical/regulatory milestone. Don't keep it to ourselves, let folks know.
Please send us a message or call us for an appointment.
7707 Fannin Street, Suite 200, Houston, Texas 77054, United States
Monday - Friday: 8:00am - 5:00pm
Saturday - Sunday: Closed